Lakefront Biotherapeutics (LKFT) Beginning Cash Balance (2018 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Beginning Cash Balance for 5 consecutive years, with $100.0 million the latest figure, recorded in Q1 2026.

• Quarterly Beginning Cash Balance rose 36.78% year-over-year to $100.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $173.1 million (down 34.17% YoY) and the FY2016 annual result came in at $491.1 million, up 81.3% from the prior year.
• Beginning Cash Balance climbed to $100.0 million in Q1 2026 per LKFT's latest filing, from $73.1 million in the prior quarter.
• Over the last five years, Beginning Cash Balance for LKFT reached as high as $189.8 million in Q1 2024 and fell as low as $73.1 million in Q1 2025.
• A 3-year average of $121.0 million and a median of $100.0 million in 2026 frame the typical range for Beginning Cash Balance.
• Annual changes were most pronounced in 2025 — Beginning Cash Balance tumbled 61.49% — and 2026, when it jumped 36.78%.
• Year by year, Beginning Cash Balance stood at $189.8 million in 2024, then slumped by 61.49% to $73.1 million in 2025, then surged by 36.78% to $100.0 million in 2026.
• According to Business Quant data, Beginning Cash Balance over the past three periods registered $100.0 million, $73.1 million, and $189.8 million for Q1 2026, Q1 2025, and Q1 2024 respectively.